Lee's Pharmaceutical Holdings (HKSE:00950) Common Stock: HK$29 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:00950 Lee's Pharmaceutical Holdings Ltd HKSE:00950
74 GF Score
Price HK$1.24
GF Value HK$1.69
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Lee's Pharmaceutical Holdings Common Stock?

Lee's Pharmaceutical Holdings HKSE:00950 -5.73% 74 Common Stock is HK$29 Mil as of Jun. 2026. GuruFocus rates HKSE:00950 with a GF Score™ of 74/100 and a GF Value™ of HK$1.69 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Lee's Pharmaceutical Holdings's quarterly common stock stayed the same from Jun. 2025 (HK$29 Mil) to Dec. 2025 (HK$29 Mil) and stayed the same from Dec. 2025 (HK$29 Mil) to Jun. 2026 (HK$29 Mil).

Lee's Pharmaceutical Holdings's annual common stock stayed the same from Dec. 2023 (HK$29 Mil) to Dec. 2024 (HK$29 Mil) and stayed the same from Dec. 2024 (HK$29 Mil) to Dec. 2025 (HK$29 Mil).

Lee's Pharmaceutical Holdings Common Stock Historical Data

* Premium members only.

The historical data trend for Lee's Pharmaceutical Holdings's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lee's Pharmaceutical Holdings Common Stock Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.44 29.44 29.44 29.44 29.44

Lee's Pharmaceutical Holdings Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.44 29.44 29.44 29.44 29.44
HKSE:00950
74GF Score
Lee's Pharmaceutical Holdings Ltd HKSE:00950
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lee's Pharmaceutical Holdings Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of HK$29 Mil mean?
Lee's Pharmaceutical Holdings (HKSE:00950) has a Common Stock of HK$29 Mil as of Jun. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Lee's Pharmaceutical Holdings and its competitors.
Is Lee's Pharmaceutical Holdings' Common Stock too high?
Lee's Pharmaceutical Holdings' current Common Stock is HK$29 Mil. Overall, Lee's Pharmaceutical Holdings has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lee's Pharmaceutical Holdings' Common Stock compare to ZTS?
Lee's Pharmaceutical Holdings' Common Stock of HK$29 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Lee's Pharmaceutical Holdings and its competitors. Lee's Pharmaceutical Holdings's current Common Stock is HK$29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lee's Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings (HKSE:00950) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$1.69, compared to a current price of HK$1.24 — trading 26.9% below its estimated fair value. The current Common Stock is HK$29 Mil. Lee's Pharmaceutical Holdings' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Lee's Pharmaceutical Holdings (HKSE:00950), the current Common Stock is HK$29 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lee's Pharmaceutical Holdings (HKSE:00950) Overvalued in 2026?

Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued. The current stock price of HK$1.24 is trading 26.9% below its estimated GF Value™ of HK$1.69. GuruFocus considers Lee's Pharmaceutical Holdings to be Modestly Undervalued.

Key valuation signals for HKSE:00950:

  • Common Stock: HK$29 Mil
  • GF Value™: HK$1.69 vs. price of HK$1.24 (26.9% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the HKSE:00950 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lee's Pharmaceutical Holdings Business Description

Address Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
74GF Score

Get the complete analysis for HKSE:00950

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.24
Price
HK$1.69
GF Value